Article Text

Download PDFPDF

Critical appraisal of adverse effects reporting in the ‘Treatment for Adolescents With Depression Study (TADS)’
  1. Tone Westergren1,
  2. Sigrid Narum2,
  3. Marianne Klemp3
  1. 1 Regional Medicines Information and Pharmacovigilance Centre (RELIS Sør-Øst), Department of Pharmacology, Oslo University Hospital, Oslo, Norway
  2. 2 Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway
  3. 3 Department of Pharmacology, University of Oslo, Oslo, Norway
  1. Correspondence to Tone Westergren; twesterg{at}ous-hf.no

Abstract

Objective To identify all publications from the ‘Treatment for Adolescents With Depression Study (TADS)’ and assess the findings regarding occurrence of any adverse effects in the treatment groups both for the short-term and long-term study stages.

Design Descriptive analysis of TADS publications with any information on adverse effects.

Results We identified 48 publications describing various aspects of the TADS, in which 439 adolescent patients received treatment with fluoxetine, cognitive–behavioural therapy, cognitive–behavioural therapy plus fluoxetine or placebo. Eight publications were assessed as providing some data on adverse effects. Risk of suicidal behaviour was the only adverse effect that was addressed in all publications. Several psychiatric and physical adverse effects were reported during the first 12 weeks, but not mentioned in reports from later study stages. Common adverse effects of fluoxetine, such as weight changes or sexual problems, were not identified or mentioned in the publications.

Conclusions The TADS publications do not present a comprehensive assessment of treatment risk with fluoxetine in adolescents, especially for more than 12 weeks of treatment. Risk of suicidality was the only adverse effect that was reported over time. Reporting of adverse effects was incomplete with regard to the long-term safety profile of fluoxetine.

  • clinical pharmacology
  • adverse events
  • clinical trials

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors SN suggested the research question. All authors discussed and defined the project. TW and SN researched the literature and made the initial assessments. All authors discussed the publications included in the study, including interpretation and presentation of results. TW drafted and finalised the manuscript as lead author. SN and MK commented on the draft and revised the manuscript at all stages. All authors agreed to the final version of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement No additional data are available.

  • Patient consent for publication Not required.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.